Cancer is a major healthcare burden across the world and impacts not only the people diagnosed with various cancers but also their families, carers, and healthcare systems. With advances in the diagnosis and treatment, more people are diagnosed early and receive treatments for a disease where few treatments options were previously available. As a result, the survival of patients with cancer has steadily improved and, in most cases, patients who are not cured may receive multiple lines of treatment, often with financial consequences for the patients, insurers and healthcare systems. Although many books exist that address economic evaluation, Economic Evaluation of Cancer Drugs using Clinical Trial and Real World Data is the first unified text that specifically addresses the economic evaluation of cancer drugs. The authors discuss how to perform cost-effectiveness analyses while emphasising the strategic importance of designing cost-effectiveness into cancer trials and building robust economic evaluation models that have a higher chance of reimbursement if truly cost-effective. They cover the use of real-world data using cancer registries and discuss how such data can support or complement clinical trials with limited follow up. Lessons learned from failed reimbursement attempts, factors predictive of successful reimbursement and the different payer requirements across major countries including US, Australia, Canada, UK, Germany, France and Italy are also discussed. The book includes many detailed practical examples, case studies and thought-provoking exercises for use in classroom and seminar discussions. Iftekhar Khan is a medical statistician and health economist and a lead statistician at Oxford Unviersity’s Center for Statistics in Medicine. Professor Khan is also a Senior Research Fellow in Health Economics at University of Warwick and is a Senior Statistical Assessor within the Licensing Division of the UK Medicine and Health Regulation Agency. Ralph Crott is a former professor in Pharmacoeconomics at the University of Montreal in Quebec, Canada and former head of the EORTC Health Economics Unit and former senior health economist at the Belgian HTA organization. Zahid Bashir has over twelve years experience working in the pharmaceutical industry in medical affairs and oncology drug development where he is involved in the design and execution of oncology clinical trials and development of reimbursement dossiers for HTA submission.
Cancer is a major healthcare burden across the world and impacts not only the people diagnosed with various cancers but also their families, carers, and healthcare systems. With advances in the diagnosis and treatment, more people are diagnosed early and receive treatments for a disease where few treatments options were previously available. As a result, the survival of patients with cancer has steadily improved and, in most cases, patients who are not cured may receive multiple lines of treatment, often with financial consequences for the patients, insurers and healthcare systems. Although many books exist that address economic evaluation, Economic Evaluation of Cancer Drugs using Clinical Trial and Real World Data is the first unified text that specifically addresses the economic evaluation of cancer drugs. The authors discuss how to perform cost-effectiveness analyses while emphasising the strategic importance of designing cost-effectiveness into cancer trials and building robust economic evaluation models that have a higher chance of reimbursement if truly cost-effective. They cover the use of real-world data using cancer registries and discuss how such data can support or complement clinical trials with limited follow up. Lessons learned from failed reimbursement attempts, factors predictive of successful reimbursement and the different payer requirements across major countries including US, Australia, Canada, UK, Germany, France and Italy are also discussed. The book includes many detailed practical examples, case studies and thought-provoking exercises for use in classroom and seminar discussions. Iftekhar Khan is a medical statistician and health economist and a lead statistician at Oxford Unviersity's Center for Statistics in Medicine. Professor Khan is also a Senior Research Fellow in Health Economics at University of Warwick and is a Senior Statistical Assessor within the Licensing Division of the UK Medicine and Health Regulation Agency. Ralph Crott is a former professor in Pharmacoeconomics? at the University of Montreal in Quebec, Canada and former head of the EORTC Health Economics Unit and former senior health economist at the Belgian HTA organization. Zahid Bashir has over twelve years experience working in the pharmaceutical industry in medical affairs and oncology drug development where he is involved in the design and execution of oncology clinical trials and development of reimbursement dossiers for HTA submission.
This book covers various topics, from thermal-hydraulic analysis to the safety analysis of nuclear power plant. It does not focus only on current power plant issues. Instead, it aims to address the challenging ideas that can be implemented in and used for the development of future nuclear power plants. This book will take the readers into the world of innovative research and development of future plants. Find your interests inside this book!
Cancer is a major healthcare burden across the world and impacts not only the people diagnosed with various cancers but also their families, carers, and healthcare systems. With advances in the diagnosis and treatment, more people are diagnosed early and receive treatments for a disease where few treatments options were previously available. As a result, the survival of patients with cancer has steadily improved and, in most cases, patients who are not cured may receive multiple lines of treatment, often with financial consequences for the patients, insurers and healthcare systems. Although many books exist that address economic evaluation, Economic Evaluation of Cancer Drugs using Clinical Trial and Real World Data is the first unified text that specifically addresses the economic evaluation of cancer drugs. The authors discuss how to perform cost-effectiveness analyses while emphasising the strategic importance of designing cost-effectiveness into cancer trials and building robust economic evaluation models that have a higher chance of reimbursement if truly cost-effective. They cover the use of real-world data using cancer registries and discuss how such data can support or complement clinical trials with limited follow up. Lessons learned from failed reimbursement attempts, factors predictive of successful reimbursement and the different payer requirements across major countries including US, Australia, Canada, UK, Germany, France and Italy are also discussed. The book includes many detailed practical examples, case studies and thought-provoking exercises for use in classroom and seminar discussions. Iftekhar Khan is a medical statistician and health economist and a lead statistician at Oxford Unviersity’s Center for Statistics in Medicine. Professor Khan is also a Senior Research Fellow in Health Economics at University of Warwick and is a Senior Statistical Assessor within the Licensing Division of the UK Medicine and Health Regulation Agency. Ralph Crott is a former professor in Pharmacoeconomics at the University of Montreal in Quebec, Canada and former head of the EORTC Health Economics Unit and former senior health economist at the Belgian HTA organization. Zahid Bashir has over twelve years experience working in the pharmaceutical industry in medical affairs and oncology drug development where he is involved in the design and execution of oncology clinical trials and development of reimbursement dossiers for HTA submission.
The Ahmadiyya Case of South Africa is an account of the litigation in Cape Town between Muslims of the Lahore Ahmadiyya Movement and local Sunni Muslim religious bodies which ended in November 1985 with the court judgment declaring the Lahore Ahmadiyya to be Muslims. The case was instituted by Lahore Ahmadiyya members as they were being defamed as unbelievers and apostates by the local anti-Ahmadiyya Ulama and denied their religious rights as Muslims. During the litigation the anti-Ahmadiyya parties, the defendants, had the support of the topmost theological and legal experts from Pakistan where the Ahmadiyya are officially branded as non-Muslims by law. But the defendants and their expert witnesses never had the intention of appearing in court as their false propaganda could never succeed in a fair and impartial forum. This book contains a history of the case and reactions to the judgment. It reproduces the text of the judgment, and consists mostly of the extensive documentary evidence submitted by the Lahore Ahmadiyya side, prepared by Maulana Hafiz Sher Mohammad and translated into English by Zahid Aziz.
After The Assassination Of Benazir Bhutto, Pakistan Stands On The Edge Of An Abyss Into Which It May Plunge The World. As This Nuclear Power Nation, The Front Line Of The West&Rsquo;S Struggle Against Al Qaeda, Enters The Worst Political Crisis In Its History, Zahid Hussain&Rsquo;S Acclaimed And Updated Book Unravels The Key Questions: Who Really Controls The Country? Will Pakistan Be Talibanized? Has Al Qaeda Infiltrated The State? After 9/11, Pakistan&Rsquo;S Controversial President, Pervez Musharraf Stunned The World By Announcing His Support For America&Rsquo;S &Lsquo;War On Terror&Rsquo;. But In Pakistan, As Zahid Hussain Reveals, Nothing Is As It Seems. The Author Documents For The First Time In Detail The Incestuous Relationship Between Pakistan&Rsquo;S Jihadis And Its All-Powerful Military Intelligence Agency&Mdash;The Isi. He Penetrates The Jihadi Networks, Revealing Their Sources Of Funding, And Their Links With The Taliban And Al Qaeda, And Based On Exclusive Interviews With Key Players, He Shows Us The Fall-Out From Musharraf&Rsquo;S Momentous Decision To Support America. From The Dangerous Mountain Passes Of Waziristan To The Mess Tables Of Rawalpindi And The Sectarian Madrassas Of The Punjab, Hussain Portrays A Country Which Was Already Seething With Unrest Before Political Violence Claimed Its Highest Profile Victim In December 2007. As The Author Shows, Whoever Was Behind The Assassination Of Benazir Bhutto, Its Main Effect Has Been To Accelerate The Country&Rsquo;S Fragmentation, Creating A Level Of Uncertainty And Chaos From Which Only Extremists And Terrorists Can Benefit. Whatever Lies In Wait For Pakistan&Mdash;Talibanization, Civil War Or Worse&Mdash;It Will Have Grave Implications For The Entire World.
This book has been published at the centenary of the Ahmadiyya Anjuman Isha‘at Islam, or Ahmadiyya Association for the Propagation of Islam, known also as the Lahore Ahmadiyya Movement, which was founded at Lahore in May 1914. It is the result of new research and brings to light some forgotten and buried material. It shows that the Lahore Ahmadiyya is a direct continuation of the Ahmadiyya Movement as founded by Hazrat Mirza Ghulam Ahmad (d. 1908) and as led afterwards by his successor Hazrat Maulana Nur-ud-Din (d. 1914). It seeks to preserve the beliefs, mission and goals of this Movement as set down by these two guiding lights.
This book analyzes the importance of informal social protection provided by religious institutions such as madrassas in a low-income country such as Pakistan. This book explains that Madrassas are religious schools that have existed in many Muslim countries for centuries and contributed significantly to preserving, forming, and extending human knowledge in medieval times. Further, madrassas are now more commonly viewed as the providers of a narrow education, supporting religious fundamentalism, that may lead to terrorism. However, this book asserts that education is not the only function performed by madrassas. They are a significant source of welfare support for the vulnerable and marginalized households in many low-income countries. This book helps the readers to understand the concept of informal social protection not conceptualized previously. In addition, its various attributes and institutions providing such a form of welfare worldwide are explained in detail; analyzing the usefulness of such a form of social protection would benefit readers of social policy, national governments, and international donor/aid agencies. This book also provides a prescriptive framework for integrating formal and informal social protection. This book provides a new "Multiple Regime Framework", for identifying various regimes in one country at one point in time by applying a novel data collection and analysis methodology. The application of this framework would be of particular interest to social policy scholars, national governments, and donor/aid agencies because it will result in better targeting of social protection policies in the wake of fiscal constraints. Lastly, this book provides a novel data collection and analysis strategy that will benefit the reader of research methodology, development consultants, donor agencies, and policy practitioners interested in using artificial intelligence to make informed and targeted policy decisions.
This booklet is compiled at the centenary of the publication, in 1917 in England, of the English translation and commentary of the Quran by Maulana Muhammad Ali — the first such work by a Muslim to be printed and published in the West, the first such work by a Muslim to be widely available in the world. It recounts the history of how the Maulana carried out this unprecedented project, its publication and the reviews it received. Its influence on later translations is discussed in detail. Maulana Muhammad Ali’s thorough revision of it to produce the 1951 edition, is then covered. Information is also provided about editions produced after his death.
Thank you for visiting our website. Would you like to provide feedback on how we could improve your experience?
This site does not use any third party cookies with one exception — it uses cookies from Google to deliver its services and to analyze traffic.Learn More.